Study to be presented at 3rd Global NASH Congress in London, U.K., February 10, 11 Data show, for the first time, that INDY inhibition attenuates
Dr Morris will lead Enterprise’s therapeutics development strategy and drive the Company’s two lead respiratory programmes through the clinic Brighton, UK, 10 February 2020: Enterprise
WALTHAM Mass., Jan. 13, 2020 – Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global biopharmaceutical company pioneering targeted C3 therapies, today announced the closing of its previously
“TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis” published in American Journal of Respiratory and Critical Care Medicine Paper demonstrates first
Pegcetacoplan met the primary endpoint in the PEGASUS study, demonstrating superiority to eculizumab (p<0.0001) with an improvement in adjusted means of 3.8 g/dL of hemoglobin
First program from the Topas platform to enter clinical testing PM203 is one of several proprietary programs being developed by Topas Pemphigus vulgaris is an
To accelerate development of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology Edinburgh, United Kingdom – Edinburgh Molecular Imaging Ltd (EMI), a
Epidarex’s therapeutic discovery engine will identify innovative early stage assets, providing hands-on scientific support and funding to drive drug discovery projects Exeed will mould and
18 month project in collaboration with University of Leeds and Medicines Discovery Catapult will deliver a new compound for treatment of thrombosis Currently available anticoagulants
Novel anticoagulants to minimise bleeding risk by targeting activated Factor XII Builds on a decade of academic research into Factor XII Investment round led by